- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation begins with an overview of radium-223's mechanism as a targeted alpha emitter and its historical efficacy in the ALSYMPCA trial, before exploring its underutilization despite FDA approval. The discussion...
|
- Details
- Wilbert Zwart joins Neeraj Agarwal to discuss research on epigenetic targeting in prostate cancer. The discussion examines histone markers in metastatic castration-resistant prostate cancer (mCRPC) patients to predict response to enzalutamide treatment. Using patient-derived xenografts and computational modeling, the research identifies HDAC3 as a key target and demonstrates synergistic effects wh...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Bram De Laere discusses the ProBio trial, a platform study for metastatic prostate cancer. Dr. De Laere explains the trial's unique design, which uses circulating tumor DNA analysis to guide treatment decisions and evaluate multiple biomarker-therapy combinations simultaneously. The study demonstrates that AR pathway inhibitors generally outperform taxane-based chemotherapy in mCRPC patients, with...
|
- Details
- Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial's design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2 m...
|
- Details
- Oliver Sartor interviews William Kevin Kelly about findings on AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer. Dr. Kelly discusses the drug's mechanism, dosing optimization, and efficacy in heavily pretreated patients. He highlights the manageable cytokine release syndrome and the need to address musculoskeletal side effects. The conversation covers impressive...
|
- Details
- Himisha Beltran discuses DLL3, a promising target for neuroendocrine prostate cancer treatment. Dr. Beltran explains that DLL3 is highly expressed in neuroendocrine and small cell prostate cancers, making it an attractive therapeutic target. She reviews recent clinical trials of DLL3-targeted T-cell engagers, including Tarlatamab and MK-6070, highlighting their potential efficacy in treating neuro...
|
